Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 702

1.

18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.

Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW.

J Nucl Med. 2009 Apr;50(4):513-9. doi: 10.2967/jnumed.108.058396. Epub 2009 Mar 16.

2.

The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.

Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B.

J Nucl Med. 2009 Apr;50(4):506-12. doi: 10.2967/jnumed.108.056382. Epub 2009 Mar 16.

3.

18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.

Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W.

Eur J Radiol. 2009 Aug;71(2):242-8. doi: 10.1016/j.ejrad.2008.04.018. Epub 2008 May 29.

PMID:
18511228
4.

Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.

Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A.

Clin Nucl Med. 2009 Dec;34(12):878-83. doi: 10.1097/RLU.0b013e3181becfe0.

PMID:
20139821
5.

F-18 FDG PET/CT in the management of thyroid cancer.

Iagaru A, Kalinyak JE, McDougall IR.

Clin Nucl Med. 2007 Sep;32(9):690-5.

PMID:
17710020
6.

The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.

Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ.

Nucl Med Commun. 2007 May;28(5):373-81.

PMID:
17414887
7.

Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.

Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, Galli G, Fanti S, Giordano A.

Nucl Med Commun. 2011 Jul;32(7):575-82. doi: 10.1097/MNM.0b013e328345a340.

PMID:
21471850
8.

PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.

Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D.

J Nucl Med. 2005 May;46(5):758-62.

9.

Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.

Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E.

J Nucl Med. 2004 Feb;45(2):272-8.

10.

PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report.

Rutten I, Cabay JE, Withofs N, Lemaire C, Aerts J, Baart V, Hustinx R.

J Nucl Med. 2007 May;48(5):720-5.

11.

Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.

Perri M, Erba P, Volterrani D, Guidoccio F, Lazzeri E, Caramella D, Mariani G.

AJR Am J Roentgenol. 2011 Jul;197(1):209-16. doi: 10.2214/AJR.10.5342.

PMID:
21701032
12.

Fever of unknown origin: the role of 18F-FDG PET/CT.

Keidar Z, Gurman-Balbir A, Gaitini D, Israel O.

J Nucl Med. 2008 Dec;49(12):1980-5. doi: 10.2967/jnumed.108.054692. Epub 2008 Nov 7.

13.

Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.

Moreau A, Giraudet AL, Kryza D, Borson-Chazot F, Bournaud C, Mognetti T, Lifante JC, Combemale P, Giammarile F, Houzard C.

Nucl Med Commun. 2017 Sep;38(9):771-779. doi: 10.1097/MNM.0000000000000708.

PMID:
28704339
14.

18F-fluoride PET/CT for bone scanning. Role of attenuation correction.

Nagarajah J, Dannat T, Hartung V, Bockisch A, Rosenbaum-Krumme S.

Nuklearmedizin. 2012;51(3):84-7. doi: 10.3413/Nukmed-0433-11-10. Epub 2012 Feb 27.

PMID:
22366817
15.

Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study.

Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, Bui F.

Nucl Med Commun. 2006 Jul;27(7):583-7.

PMID:
16794519
16.

A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.

Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, Feng H, Tan Y, Zhao Z, Wu W.

J Nucl Med. 2008 Feb;49(2):186-94. doi: 10.2967/jnumed.107.044966. Epub 2008 Jan 16.

17.

Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.

Yamaguchi T, Ueda O, Hara H, Sakai H, Kida T, Suzuki K, Adachi S, Ishii K.

Ann Nucl Med. 2009 Jan;23(1):65-71. doi: 10.1007/s12149-008-0206-4. Epub 2009 Feb 11.

PMID:
19205840
19.

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.

J Nucl Med. 2009 Aug;50(8):1214-21. doi: 10.2967/jnumed.108.060236. Epub 2009 Jul 17.

20.

Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S.

J Nucl Med. 2005 Oct;46(10):1642-9.

Supplemental Content

Support Center